

Conrad C Weihl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4223278/publications.pdf>

Version: 2024-02-01

70
papers

9,258
citations

108046

37
h-index

93651

72
g-index

78
all docs

78
docs citations

78
times ranked

18161
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	4.3	3,122
2	Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. <i>Nature</i> , 2013, 495, 467-473.	13.7	1,249
3	Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. <i>Journal of Cell Biology</i> , 2009, 187, 875-888.	2.3	444
4	Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. <i>Nature Neuroscience</i> , 2014, 17, 664-666.	7.1	398
5	The VCP/p97 system at a glance: connecting cellular function to disease pathogenesis. <i>Journal of Cell Science</i> , 2014, 127, 3877-83.	1.2	329
6	<scp>VCP</scp> /p97 cooperates with <scp>YOD</scp> 1, <scp>UBXD</scp> 1 and <scp>PLAA</scp> to drive clearance of ruptured lysosomes by autophagy. <i>EMBO Journal</i> , 2017, 36, 135-150.	3.5	259
7	Exploiting macrophage autophagy-lysosomal biogenesis as a therapy for atherosclerosis. <i>Nature Communications</i> , 2017, 8, 15750.	5.8	258
8	Endolysosomal sorting of ubiquitylated caveolin-1 is regulated by VCP and UBXD1 and impaired by VCP disease mutations. <i>Nature Cell Biology</i> , 2011, 13, 1116-1123.	4.6	213
9	Valosin-containing protein disease: Inclusion body myopathy with Paget's disease of the bone and fronto-temporal dementia. <i>Neuromuscular Disorders</i> , 2009, 19, 308-315.	0.3	205
10	Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation. <i>Human Molecular Genetics</i> , 2006, 15, 189-199.	1.4	169
11	Exome sequencing reveals <i>DNAJB6</i> mutations in dominantly inherited myopathy. <i>Annals of Neurology</i> , 2012, 71, 407-416.	2.8	148
12	Interaction with Polyglutamine Aggregates Reveals a Q/N-rich Domain in TDP-43. <i>Journal of Biological Chemistry</i> , 2010, 285, 26304-26314.	1.6	138
13	A novel mutation in VCP causes Charcot-Marie-Tooth Type 2 disease. <i>Brain</i> , 2014, 137, 2897-2902.	3.7	116
14	Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. <i>Neurology</i> , 2006, 67, 500-501.	1.5	111
15	Keap1/Cullin3 Modulates p62/SQSTM1 Activity via UBA Domain Ubiquitination. <i>Cell Reports</i> , 2017, 19, 188-202.	2.9	110
16	Specific Inhibition of p97/VCP ATPase and Kinetic Analysis Demonstrate Interaction between D1 and D2 ATPase Domains. <i>Journal of Molecular Biology</i> , 2014, 426, 2886-2899.	2.0	103
17	Prion-like nuclear aggregation of TDP-43 during heat shock is regulated by HSP40/70 chaperones. <i>Human Molecular Genetics</i> , 2014, 23, 157-170.	1.4	102
18	Transgenic expression of inclusion body myopathy associated mutant p97/VCP causes weakness and ubiquitinated protein inclusions in mice. <i>Human Molecular Genetics</i> , 2007, 16, 919-928.	1.4	99

#	ARTICLE	IF	CITATIONS
19	Inflammatory myopathies with mitochondrial pathology and protein aggregates. <i>Journal of the Neurological Sciences</i> , 2009, 278, 25-29.	0.3	91
20	Altered cofactor regulation with disease-associated p97/VCP mutations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1705-14.	3.3	87
21	Motor neuron involvement in multisystem proteinopathy. <i>Neurology</i> , 2013, 80, 1874-1880.	1.5	85
22	High-protein diets increase cardiovascular risk by activating macrophage mTOR to suppress mitophagy. <i>Nature Metabolism</i> , 2020, 2, 110-125.	5.1	85
23	Motor neuron disease associated with copper deficiency. <i>Muscle and Nerve</i> , 2006, 34, 789-793.	1.0	76
24	TIA1 variant drives myodegeneration in multisystem proteinopathy with SQSTM1 mutations. <i>Journal of Clinical Investigation</i> , 2018, 128, 1164-1177.	3.9	75
25	<i>SQSTM1</i> splice site mutation in distal myopathy with rimmed vacuoles. <i>Neurology</i> , 2015, 85, 665-674.	1.5	74
26	Myopathy associated BAG3 mutations lead to protein aggregation by stalling Hsp70 networks. <i>Nature Communications</i> , 2018, 9, 5342.	5.8	65
27	Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis. <i>Annals of Neurology</i> , 2017, 81, 227-239.	2.8	59
28	mTOR dysfunction contributes to vacuolar pathology and weakness in valosin-containing protein associated inclusion body myopathy. <i>Human Molecular Genetics</i> , 2013, 22, 1167-1179.	1.4	58
29	Targeted sequencing and identification of genetic variants in sporadic inclusion body myositis. <i>Neuromuscular Disorders</i> , 2015, 25, 289-296.	0.3	56
30	Estimating prevalence for limb-girdle muscular dystrophy based on public sequencing databases. <i>Genetics in Medicine</i> , 2019, 21, 2512-2520.	1.1	56
31	Molecular and cellular basis of genetically inherited skeletal muscle disorders. <i>Nature Reviews Molecular Cell Biology</i> , 2021, 22, 713-732.	16.1	55
32	Sporadic inclusion body myositis: possible pathogenesis inferred from biomarkers. <i>Current Opinion in Neurology</i> , 2010, 23, 482-488.	1.8	47
33	Regulation of SQSTM1/p62 via UBA domain ubiquitination and its role in disease. <i>Autophagy</i> , 2017, 13, 1615-1616.	4.3	47
34	Myopathy-causing Mutations in an HSP40 Chaperone Disrupt Processing of Specific Client Conformers. <i>Journal of Biological Chemistry</i> , 2014, 289, 21120-21130.	1.6	46
35	VCP maintains lysosomal homeostasis and TFEB activity in differentiated skeletal muscle. <i>Autophagy</i> , 2019, 15, 1082-1099.	4.3	44
36	Quantification of autophagy flux using LC3 ELISA. <i>Analytical Biochemistry</i> , 2017, 530, 57-67.	1.1	43

#	ARTICLE	IF	CITATIONS
37	CANOMAD and other chronic ataxic neuropathies with disialosyl antibodies (CANDA). <i>Journal of Neurology</i> , 2018, 265, 1402-1409.	1.8	40
38	215th ENMC International Workshop VCP-related multi-system proteinopathy (IBMPFD) 13-15 November 2015, Heemskerk, The Netherlands. <i>Neuromuscular Disorders</i> , 2016, 26, 535-547.	0.3	38
39	Desmin forms toxic, seeding-competent amyloid aggregates that persist in muscle fibers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 16835-16840.	3.3	36
40	Increased autophagy accelerates colchicine-induced muscle toxicity. <i>Autophagy</i> , 2013, 9, 2115-2125.	4.3	35
41	Myofibrillar disruption and RNA-binding protein aggregation in a mouse model of limb-girdle muscular dystrophy 1D. <i>Human Molecular Genetics</i> , 2015, 24, 6588-6602.	1.4	31
42	Loss of lipin 1-mediated phosphatidic acid phosphohydrolase activity in muscle leads to skeletal myopathy in mice. <i>FASEB Journal</i> , 2019, 33, 652-667.	0.2	30
43	Multisystem Proteinopathy Due to VCP Mutations: A Review of Clinical Heterogeneity and Genetic Diagnosis. <i>Genes</i> , 2022, 13, 963.	1.0	28
44	Neuronal VCP loss of function recapitulates FTLTDP pathology. <i>Cell Reports</i> , 2021, 36, 109399.	2.9	25
45	Mutations in the J domain of DNAJB6 cause dominant distal myopathy. <i>Neuromuscular Disorders</i> , 2020, 30, 38-46.	0.3	20
46	Autophagic vacuolar pathology in desminopathies. <i>Neuromuscular Disorders</i> , 2015, 25, 199-206.	0.3	19
47	Clinical utility of anti-cytosolic 5'-nucleotidase 1A antibody in idiopathic inflammatory myopathies. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 571-578.	1.7	18
48	Rare Manifestation of a c.290 C>T, p.Gly97Glu VCP Mutation. <i>Case Reports in Genetics</i> , 2015, 2015, 1-5.	0.1	16
49	A metastable subproteome underlies inclusion formation in muscle proteinopathies. <i>Acta Neuropathologica Communications</i> , 2019, 7, 197.	2.4	16
50	Novel GNE mutations in two phenotypically distinct HIBM2 patients. <i>Neuromuscular Disorders</i> , 2011, 21, 102-105.	0.3	15
51	Limb-girdle muscular dystrophy: A perspective from adult patients on what matters most. <i>Muscle and Nerve</i> , 2019, 60, 419-424.	1.0	15
52	Lithium chloride corrects weakness and myopathology in a preclinical model of LGMD1D. <i>Neurology: Genetics</i> , 2019, 5, e318.	0.9	15
53	VCP suppresses proteopathic seeding in neurons. <i>Molecular Neurodegeneration</i> , 2022, 17, 30.	4.4	15
54	Inhibition of DNAJ-HSP70 interaction improves strength in muscular dystrophy. <i>Journal of Clinical Investigation</i> , 2020, 130, 4470-4485.	3.9	14

#	ARTICLE	IF	CITATIONS
55	Monitoring Autophagy in the Treatment of Protein Aggregate Diseases: Steps Toward Identifying Autophagic Biomarkers. <i>Neurotherapeutics</i> , 2013, 10, 383-390.	2.1	11
56	Phenotypic diversity in an international Cure VCP Disease registry. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 267.	1.2	11
57	Homozygous recessive MYH2 mutation mimicking dominant MYH2 associated myopathy. <i>Neuromuscular Disorders</i> , 2018, 28, 675-679.	0.3	10
58	Comparisons of ELISA and Western blot assays for detection of autophagy flux. <i>Data in Brief</i> , 2017, 13, 696-699.	0.5	8
59	Randomized phase 2 study of <scp>ACE</scp>â€œ083, a <scp>muscleâ€promoting</scp> agent, in facioscapulohumeral muscular dystrophy. <i>Muscle and Nerve</i> , 2022, 66, 50-62.	1.0	8
60	Another VCP interactor: NF is enough. <i>Journal of Clinical Investigation</i> , 2011, 121, 4627-4630.	3.9	7
61	Client processing is altered by novel myopathy-causing mutations in the HSP40 J domain. <i>PLoS ONE</i> , 2020, 15, e0234207.	1.1	6
62	Sporadic Inclusion Body Myositis and Other Rimmed Vacuolar Myopathies. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 1586-1598.	0.4	6
63	Cystinosis distal myopathy, novel clinical, pathological and genetic features. <i>Neuromuscular Disorders</i> , 2017, 27, 873-878.	0.3	5
64	Optimizing hand-function patient outcome measures for inclusion body myositis. <i>Neuromuscular Disorders</i> , 2020, 30, 807-814.	0.3	5
65	Loss-of-function mutation in VCP mimics the characteristic pathology as in FTLT-TARDBP. <i>Autophagy</i> , 2021, 17, 4502-4503.	4.3	5
66	A cross-sectional study of hand function in inclusion body myositis: Implications for functional rating scale. <i>Neuromuscular Disorders</i> , 2020, 30, 200-206.	0.3	4
67	Current and Future Approaches to Classify VUSs in LGMD-Related Genes. <i>Genes</i> , 2022, 13, 382.	1.0	3
68	Progression to Loss of Ambulation Among Patients with Autosomal Recessive Limb-girdle Muscular Dystrophy: A Systematic Review. <i>Journal of Neuromuscular Diseases</i> , 2022, , 1-16.	1.1	3
69	Establishing prevalence in rare neuromuscular diseases. <i>Neurology: Genetics</i> , 2017, 3, e146.	0.9	1
70	Mdx mice have a defect in autophagy that is restored by rapamycinâ€loaded nanoparticle treatment. <i>FASEB Journal</i> , 2012, 26, 396.5.	0.2	1